At presentation of primary breast cancer, only small proportion of the patients (5 of 18, 27.7%) could have received HER2-directed therapy among the patients who underwent systemic chemotherapy in patients with HER2 positive. This evidence concerns the gene ERBB2 and breast carcinoma.